Literature DB >> 19886641

Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement?

Christopher J Endres1, Michael G Endres, Jashvant D Unadkat.   

Abstract

The interdependence of both transport and metabolism on the disposition of drugs has recently gained heightened attention in the literature, and has been termed the "interplay of transport and metabolism". Such "interplay" is observed when inhibition of biliary clearance of a drug results in an "apparent" increase in the metabolic clearance of the drug or vice versa. In this manuscript, we derived and explored through simulations a physiological-based pharmacokinetic model that integrates both transport and metabolism and explains the "apparent" dependence of hepatic clearance on both these processes. In addition, we show that the phenomenon of hepatic "transport-metabolism interplay" is a result of using the plasma concentration as a point of reference when calculating metabolic or biliary clearance, and this interplay is maximal when the drug is actively transported into the hepatocytes (i.e., hepatocyte sinusoidal influx clearance is greater than the sinusoidal efflux clearance). When the hepatic drug concentration is used as a reference point to calculate metabolic or biliary clearance, this interplay ceases to exist. A mechanistic understanding of this interplay phenomenon can be used to explain the somewhat paradoxical results that may be observed in drug-drug interaction studies when a drug is cleared by both metabolism and biliary excretion. That is, when one of these two pathways is inhibited, the other pathway appears to be induced or activated. This interplay results in an increase in hepatic drug concentrations and therefore has implications for the hepatic efficacy and toxicity of a drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19886641      PMCID: PMC2801584          DOI: 10.1021/mp9002392

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   5.364


  24 in total

1.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

Authors:  R S Obach
Journal:  Drug Metab Dispos       Date:  1999-11       Impact factor: 3.922

Review 2.  Prediction of intestinal first-pass drug metabolism.

Authors:  Jiansong Yang; Masoud Jamei; Karen Rowland Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Curr Drug Metab       Date:  2007-10       Impact factor: 3.731

Review 3.  Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake.

Authors:  M Baker; T Parton
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

4.  Organ clearance concepts: new perspectives on old principles.

Authors:  G L Sirianni; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

5.  Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes.

Authors:  Y Kwon; M E Morris
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

6.  In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.

Authors:  Michiharu Kageyama; Hitomi Namiki; Hiroto Fukushima; Yukako Ito; Nobuhito Shibata; Kanji Takada
Journal:  Biol Pharm Bull       Date:  2005-02       Impact factor: 2.233

Review 7.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

Authors:  Yoshihisa Shitara; Yuichi Sugiyama
Journal:  Pharmacol Ther       Date:  2006-05-22       Impact factor: 12.310

Review 8.  Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans.

Authors:  Satoshi Kitamura; Kazuya Maeda; Yuichi Sugiyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-07       Impact factor: 3.000

Review 9.  Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs.

Authors:  Anne T Nies; Matthias Schwab; Dietrich Keppler
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-05       Impact factor: 4.481

10.  Transport-metabolism interplay: LXRalpha-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells.

Authors:  Tatsuhiko Adachi; Hiroshi Nakagawa; Yuichiro Hagiya; Tatsuya Yasuoka; Toshihisa Ishikawa
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

View more
  6 in total

1.  Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

Authors:  Anand K Deo; Bhagwat Prasad; Larissa Balogh; Yurong Lai; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2012-02-08       Impact factor: 3.922

2.  When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions.

Authors:  Gabriela I Patilea-Vrana; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2018-08-16       Impact factor: 3.922

3.  Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A.

Authors:  Sarah Billington; Steven Shoner; Scott Lee; Kindra Clark-Snustad; Matthew Pennington; David Lewis; Mark Muzi; Shirley Rene; Jean Lee; Tot Bui Nguyen; Vineet Kumar; Kazuya Ishida; Laigao Chen; Xiaoyan Chu; Yurong Lai; Laurent Salphati; Cornelis E C A Hop; Guangqing Xiao; Mingxiang Liao; Jashvant D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

Review 4.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

5.  Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.

Authors:  R M Franke; C S Lancaster; C J Peer; A A Gibson; A M Kosloske; S J Orwick; R H Mathijssen; W D Figg; S D Baker; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2011-03-30       Impact factor: 6.875

6.  Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model.

Authors:  G Patilea-Vrana; J D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2016-08-27       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.